Revlimid is the drug that broke the usual rules about what happens when a generic arrives. Generic lenalidomide has been on U.S. pharmacy shelves since March 2022, there are now nineteen approved generic applications with active prescription marketing status in FDA’s Drugs@FDA database, and yet the cash price never fell the way a nineteen-competitor generic normally falls. The reason is written into Bristol Myers Squibb’s own SEC filings.
The second thing to know is that Revlimid is priced per capsule, not per milligram. A 2.5 mg capsule and a 25 mg capsule cost within nine cents of each other. What actually changes your monthly bill is how many capsules the regimen calls for, and that depends on whether you are on a 21-days-of-28 schedule or a continuous one. Every figure below was researched on September 3, 2026.
What Does Revlimid Cost Without Insurance?
Dosing comes from the FDA-approved prescribing information: 25 mg once daily on days 1 through 21 of repeated 28-day cycles for multiple myeloma combination therapy, and 10 mg once daily continuously on days 1 through 28 for maintenance after autologous stem cell transplant. The label also instructs pharmacies to “dispense no more than a 28-day supply,” which is why you cannot buy this drug three months at a time.
Cash retail comes from the Drugs.com price guide. The Medicare column is 2024 average spending per dosage unit and per prescription claim from the CMS Part D Spending by Drug file, the most recent year published. There is no NADAC acquisition benchmark for this molecule at all.
| Revlimid / lenalidomide purchase | Low | Average | High |
|---|---|---|---|
| Brand Revlimid, one capsule (any strength) | $854.82 | $863.03 | $871.24 |
| Brand Revlimid, 21-capsule cycle (15, 20 or 25 mg) | $17,951.28 | $18,123.69 | $18,296.10 |
| Brand Revlimid, 28-capsule cycle (2.5, 5 or 10 mg) | $23,935.04 | $24,163.60 | $24,392.15 |
| Generic lenalidomide, one capsule (25 mg) | $301.76 | $655.88 | $711.83 |
| Generic lenalidomide, 21-capsule cycle (25 mg) | $6,336.91 | $13,773.39 | $14,948.41 |
| Generic lenalidomide, 28-capsule cycle (10 mg) | $8,446.64 | $18,364.52 | $20,977.06 |
| Medicare Part D average paid per Revlimid claim, 2024 | $17,426.03 | $17,426.03 | $17,426.03 |
| Medicare Part D average paid per generic lenalidomide claim, 2024 | $13,333.14 | $13,333.14 | $13,333.14 |
| BMS co-pay card price, commercial insurance only | $0 | $0 | $0 |
The low and high on the brand rows are the two independent per-capsule reads, $854.82 from CMS Part D and $871.24 from Drugs.com cash retail. On the generic rows the low and high are the actual published spread across labelers on Drugs.com, and the middle column is the CMS Part D weighted average of $655.88 per dosage unit carried out to a full cycle.
For scale, Medicare Part D spent $4.18 billion on brand Revlimid across 239,843 claims for 38,868 beneficiaries in 2024, plus another $2.64 billion on generic lenalidomide across 198,067 claims for 30,354 beneficiaries. Even three years into generic competition, the brand was still the larger line item.
What Drives the Price
The generic entry was volume-capped by contract. This is the whole story, and Bristol Myers Squibb states it plainly. Its Form 10-Q for the quarter ended June 30, 2026 says that in the U.S. “certain third parties have been granted volume-limited licenses to sell generic lenalidomide” and that “as of January 31, 2026, these licenses are no longer volume-limited.” For roughly four years, each generic maker could only sell a capped quantity per year. A generic that cannot take unlimited share has no reason to price like one.
That cap lifted in 2026, and the numbers moved fast. BMS reported Revlimid revenue of $425 million in the second quarter of 2026 against $838 million a year earlier, a 49 percent decline, and $773 million year to date against $1.774 billion, down 56 percent. U.S. revenue fell 52 percent in the quarter. The filing attributes this to generic erosion, “partially offset by higher average net selling prices,” which is a careful way of saying the brand raised price while losing volume.
Flat per-capsule pricing. Drugs.com lists brand Revlimid at $871.15 per capsule in the 28-count packages and $871.24 in the 21-count packages, across every strength from 2.5 mg to 25 mg. A 100-capsule bottle works out to $870.95 per capsule. This means a dose reduction saves you nothing, and a maintenance regimen taken 28 days a month costs more than an induction regimen taken 21 days a month even though the daily milligrams are far lower.
REMS distribution keeps the market narrow. BMS states in the same filing that Revlimid is distributed in the U.S. “primarily through contracted pharmacies under the Lenalidomide REMS.” Only certified prescribers and certified pharmacies can handle it. That is why the CMS National Average Drug Acquisition Cost survey, which samples invoices from retail community pharmacies, returns zero rows for both REVLIMID and LENALIDOMIDE at every strength. There is no federal acquisition benchmark to compare a quote against.
Which labeler your pharmacy stocks matters enormously. The published generic spread on a 25 mg 21-capsule cycle runs from $6,336.91 to $14,948.41. That is a $8,611 swing on the same AB-rated product for the same cycle. Ten manufacturers reported Part D volume in 2024 and more have launched since, including Accord, Padagis and Devatis with 2026 marketing start dates.
Cash Price vs. Insurance
Paying cash for this drug is almost never the right move if you have any coverage. Bristol Myers Squibb runs co-pay assistance through BMS Access Support (1-800-861-0048) for eligible commercially insured patients, and states that patients with Medicare, Medicaid or TRICARE are not eligible for BMS-sponsored co-pay programs. There is no cash discount that comes anywhere near a $0 co-pay.
If you are uninsured, BMS points you to the Bristol Myers Squibb Patient Assistance Foundation at bmspaf.org or 800-736-0003, which it describes as an independent charitable program that “provides free medication to eligible, uninsured patients who are experiencing financial hardship.” On a drug that costs $18,000 a cycle, the application is worth whatever paperwork it takes.
One practical wrinkle: because the label caps dispensing at 28 days, you cannot use the usual 90-day-fill trick to lower your per-month cost. Every fill is a fresh transaction at full price, and every fill is a fresh chance to be quoted a different number.
How to Pay Less
Ask specifically for the generic and ask which labeler. This is the single highest-value question at the counter. Because the published spread between generic labelers is more than double, and because REMS-certified pharmacies stock different manufacturers, calling two or three certified pharmacies before you transfer the prescription can be worth several thousand dollars per cycle. Ask what the cash price is for the specific labeler they have in stock, not a generic quote.
Apply for manufacturer patient assistance before your first fill. The co-pay card is closed to you if you are uninsured, so the number that matters is the foundation line, not the savings program. Approval is not instant, so start the paperwork while the prescription is still being written.
Ask whether a 340B pharmacy can dispense it. Federally qualified health centers and disproportionate-share hospitals buy at deeply discounted 340B prices and many pass that through to uninsured patients on a sliding scale. Our guide to free and sliding-scale clinics covers how to find one and what to ask for.
Use charity care if any of this care runs through a hospital. Myeloma treatment usually involves hospital-based visits, labs and imaging alongside the oral drug, and hospital charges are negotiable in a way that a pharmacy counter is not. Start with hospital charity care for eligibility, which is more generous than most people expect, then use how to negotiate medical bills once you have the statement in hand.
Get the itemized bill for the non-drug charges. The infusions, injections and scans that surround an oral regimen are where duplicate and unbundled charges hide. See how to request an itemized hospital bill and compare what you were charged against typical figures in our chemotherapy cost guide and PET scan cost guide.
Re-price at every refill, not once. Generic lenalidomide prices are actively falling now that the volume caps have lifted. A quote you got in January 2026 is not the quote you would get today. Our fair price checker gives you a benchmark to argue from.
The Bottom Line
Brand Revlimid is an $18,296 purchase for a 21-capsule cycle and a $24,392 purchase for a 28-capsule one, priced at roughly $871 per capsule no matter the strength. Generic lenalidomide can be had for as little as $6,337 per 21-capsule cycle, but only if your pharmacy happens to stock the cheapest labeler, and the most expensive generic is barely below the brand.
The thing to watch is the calendar. The volume limits on generic lenalidomide licenses came off January 31, 2026, brand revenue is down roughly half year over year, and prices are still settling. If you are paying cash, re-check the number every single cycle. For other high-cost oncology drugs where the cash and insured prices diverge sharply, see our guides to Keytruda costs and Ibrance costs.